102 related articles for article (PubMed ID: 28189004)
21. Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system.
Parada C; Hernández Losa J; Guinea J; Sánchez-Arévalo V; Fernández Soria V; Alvarez-Vallina L; Sánchez-Prieto R; Ramón y Cajal S
Cancer Gene Ther; 2003 Feb; 10(2):152-60. PubMed ID: 12536204
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir.
Wang S; Qi J; Smith M; Link CJ
Cancer Gene Ther; 2002 Jan; 9(1):1-8. PubMed ID: 11916238
[TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model.
Kothari V; Joshi G; Nama S; Somasundaram K; Mulherkar R
Int J Cancer; 2010 Feb; 126(3):733-42. PubMed ID: 19569045
[TBL] [Abstract][Full Text] [Related]
24. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration.
van der Eb MM; Cramer SJ; Vergouwe Y; Schagen FH; van Krieken JH; van der Eb AJ; Borel Rinkes IH; van de Velde CJ; Hoeben RC
Gene Ther; 1998 Apr; 5(4):451-8. PubMed ID: 9614568
[TBL] [Abstract][Full Text] [Related]
25. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET.
Tseng JC; Zanzonico PB; Levin B; Finn R; Larson SM; Meruelo D
J Nucl Med; 2006 Jul; 47(7):1136-43. PubMed ID: 16818948
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
Sterman DH; Treat J; Litzky LA; Amin KM; Coonrod L; Molnar-Kimber K; Recio A; Knox L; Wilson JM; Albelda SM; Kaiser LR
Hum Gene Ther; 1998 May; 9(7):1083-92. PubMed ID: 9607419
[TBL] [Abstract][Full Text] [Related]
27. Suicide gene therapy of human breast cancer in SCID mice model by the regulation of Tet-On.
Hu WX; Zeng ZJ; Luo SQ; Chen Q
Chin Med J (Engl); 2004 Mar; 117(3):434-9. PubMed ID: 15043787
[TBL] [Abstract][Full Text] [Related]
28. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells.
Kanazawa T; Urabe M; Mizukami H; Okada T; Kume A; Nishino H; Monahan J; Kitamura K; Ichimura K; Ozawa K
Cancer Gene Ther; 2001 Feb; 8(2):99-106. PubMed ID: 11263531
[TBL] [Abstract][Full Text] [Related]
29. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma.
Diao S; Zhang JF; Wang H; He ML; Lin MC; Chen Y; Kung HF
Proteomics; 2010 Oct; 10(20):3723-31. PubMed ID: 20859956
[TBL] [Abstract][Full Text] [Related]
30. Construction of plasmid vector pAFP-HSVtk-IRES2-EGFP and its effect on the cytotoxicity of ganciclovir to hepatocellular carcinoma.
Lai Z; Qin Q; Yu B; Xie J; Gao R; Zhang T; Li C; Niu K; Xu J
Chin Med J (Engl); 2014; 127(12):2337-41. PubMed ID: 24931253
[TBL] [Abstract][Full Text] [Related]
31. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
Yu B; Zhang Y; Zhan Y; Zha X; Wu Y; Zhang X; Dong Q; Kong W; Yu X
Oncol Rep; 2011 Jul; 26(1):255-64. PubMed ID: 21573500
[TBL] [Abstract][Full Text] [Related]
32. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.
Yao X; Yoshioka Y; Morishige T; Eto Y; Watanabe H; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Gene Ther; 2009 Dec; 16(12):1395-404. PubMed ID: 19641532
[TBL] [Abstract][Full Text] [Related]
33. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
34. Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene.
Kim YG; Bi W; Feliciano ES; Drake RR; Stambrook PJ
Cancer Gene Ther; 2000 Feb; 7(2):240-6. PubMed ID: 10770632
[TBL] [Abstract][Full Text] [Related]
35. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection.
Yao X; Yoshioka Y; Eto Y; Morishige T; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2007 Oct; 362(2):419-24. PubMed ID: 17707336
[TBL] [Abstract][Full Text] [Related]
36. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
Moriuchi S; Krisky DM; Marconi PC; Tamura M; Shimizu K; Yoshimine T; Cohen JB; Glorioso JC
Gene Ther; 2000 Sep; 7(17):1483-90. PubMed ID: 11001368
[TBL] [Abstract][Full Text] [Related]
37. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
38. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
Oh JY; Park MY; Kim DR; Lee JH; Shim SH; Chung JH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Int J Mol Med; 2010 Mar; 25(3):369-76. PubMed ID: 20127041
[TBL] [Abstract][Full Text] [Related]
39. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
40. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
Kijima T; Osaki T; Nishino K; Kumagai T; Funakoshi T; Goto H; Tachibana I; Tanio Y; Kishimoto T
Cancer Res; 1999 Oct; 59(19):4906-11. PubMed ID: 10519403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
